Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Synthetic

ADB-CHMINACAAlso known as MAB-CHMINACA

An indazole-3-carboxamide, full agonist at CB1, controlled across the Union since 2018; 13 deaths reported by three Member States.

Narcotic: named in schedule
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₁H₃₀N₄O₂

CAS 1863065-92-2

Family
Synthetic CB receptor agonistNew psychoactive substance
Molar mass
370.50 g/mol

Updated on

In plain terms

ADB-CHMINACA, also called MAB-CHMINACA, is a synthetic cannabinoid made in the laboratory. It does not exist in hemp and has nothing to do with CBD: it is found in smoking plant mixtures or as powder. It acts on the same receptors as THC. Three Member States of the Union reported 13 deaths associated with this substance, and it is classed as a narcotic in France.

Receptors and activity

Target network

CB1AgonistKi = 0 nM · human[3H]CP-55940 displacement, human CB1
  • Activates

The lower the cited value, the closer the target sits to ADB-CHMINACA: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of ADB-CHMINACA.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Map sources

  1. Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
  2. Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
  3. Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
  4. Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)

Cited values

  1. CB1AgonistKi = 0 nM · human100 out of 100

    Sommer et al. 2026, Addiction (new tab) · [3H]CP-55940 displacement, human CB1

  2. CB2Agonistno measured value cited
Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

ADB-CHMINACA is a synthetic cannabinoid receptor agonist of the indazole-3-carboxamide family. At human CB1, Sommer et al. (2026) measure an affinity of 0.0231 nM and full-agonist efficacy, whereas Δ9-THC remains a partial agonist; in rats, it fully substitutes for Δ9-THC in a discrimination test (Gatch and Forster 2018). It had been available in the Union since at least August 2014 and had been detected in 17 Member States, with more than 630 seizures; three Member States had reported 13 associated deaths (at least nine where it was the cause or likely contributed) and one Member State three non-fatal acute intoxications (Implementing Decision (EU) 2018/747). In April 2015, an outbreak of intoxications in Mississippi gave rise to 721 reported cases (11 deaths); MAB-CHMINACA or its metabolites were found in 33 of the 39 patients positive for a synthetic cannabinoid (Kasper et al. 2019). A series of 16 patients admitted to emergency departments in Germany with confirmed intake mainly presented neuropsychiatric and cardiovascular symptoms, panic attacks and trembling; all recovered (Hermanns-Clausen et al. 2026). No clinical pharmacology study was found in the sources consulted.

Key sources.

History

Source
A laboratory molecule, absent from hemp. According to Implementing Decision (EU) 2018/747, available data suggest that it is produced by chemical companies in China; it is sold as a « legal high » in smoking mixtures or as powder, and its composition is rarely stated on the packaging.

Origin

Laboratory synthesis

No biological pathway: a wholly synthetic molecule of the indazole-3-carboxamide class, described here by its chemical class only. It is produced by no plant and does not derive from cannabigerol.

Classification

Family, origin and source verification

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

indazole-3-carboxamide

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

ADB-CHMINACA (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

  1. Sommer et al. · Addiction 2026 (new tab)PMID 41423817
  2. Gatch and Forster · Psychopharmacology 2018 (new tab)PMID 29138877
  3. Carlier et al. · AAPS J 2017 (new tab)PMID 28070717
  4. Hasegawa et al. · Forensic Toxicol 2015 (new tab)PMID 26257834
  5. Hasegawa et al. · Drug Test Anal 2018 (new tab)PMID 28560823
  6. Wouters et al. · Drug Test Anal 2019 (new tab)PMID 31021521
  7. Kasper et al. · Clin Toxicol 2019 (new tab)PMID 29989463
  8. Adamowicz and Gieroń · Clin Toxicol 2016 (new tab)PMID 27227269
  9. Hermanns-Clausen et al. · Br J Clin Pharmacol 2026 (new tab)PMID 41916726
  10. Filipiuc et al. · Molecules 2026 (new tab)PMID 42451732

Identifiers

Names

Common name
ADB-CHMINACA (MAB-CHMINACA)
IUPAC name
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide
Other names
MAB-CHMINACA

Identifiers

Formula
C₂₁H₃₀N₄O₂
CAS
1863065-92-2
PubChem CID
77565944(new tab)
InChIKey
ZWCCSIUBHCZKOY-UHFFFAOYSA-N
SMILES
CC(C)(C)C(C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.